Ibopamine
Title: Ibopamine
CAS Registry Number: 66195-31-1
CAS Name: 2-Methylpropanoic acid 4-[2-(methylamino)ethyl]-1,2-phenylene ester
Additional Names: 4-[2-(methylamino)ethyl]-o-phenylene diisobutyrate; N-methyldopamine diisobutyric ester; 3,4-di-o-isobutyryl epinine
Molecular Formula: C17H25NO4
Molecular Weight: 307.38
Percent Composition: C 66.43%, H 8.20%, N 4.56%, O 20.82%
Literature References: Inotropic agent with dopaminergic and adrenergic agonist activities; converted to active metabolite, deoxyepinephrine, q.v. Prepn: C. Casagrande, G. Ferrari, DE 2734678; eidem, US 4218470 (1978, 1980 both to Simes). Pharmacology: G. F. Melloni et al., Curr. Ther. Res. 25, 406 (1979); eidem, ibid. 26, 466 (1979). Series of articles on synthesis, pharmacology, clinical efficacy: Arzneim.-Forsch. 36, 285-408 (1986). Review of pharmacodynamics, pharmacokinetics and therapeutic efficacy: J. M. Henwood, P. A. Todd, Drugs 36, 11-31 (1988). Series of articles on clinical use in congestive heart failure: Cardiology 77, Suppl. 5, 1-95 (1990). Clinical efficacy and safety in heart failure: J. R. Hampton et al., Lancet 349, 971 (1997). Clinical evaluation in diagnosis of glaucoma: G. Marchini et al., J. Ocul. Pharmacol. Ther. 17, 215 (2001); in treatment of ocular hypertony: L. C. Ugahary et al., Am. J. Ophthalmol. 141, 571 (2006).
 
Derivative Type: Hydrochloride
CAS Registry Number: 75011-65-3
Manufacturers' Codes: SB-7505
Trademarks: Inopamil (Simes); Scandine (Zambon); Trazyl (Angelini)
Molecular Formula: C17H25NO4.HCl
Molecular Weight: 343.85
Percent Composition: C 59.38%, H 7.62%, N 4.07%, O 18.61%, Cl 10.31%
Properties: Crystals from ethyl acetate, mp 132°.
Melting point: mp 132°
 
Therap-Cat: Cardiotonic. Diagnostic aid (glaucoma).
Keywords: a-Adrenergic Agonist; ?Adrenergic Agonist; Cardiotonic; Dopamine Receptor Agonist; Diagnostic Aid.

Others monographs:
Acetone CyanohydrinPyrifenoxDSPAThurfyl Nicotinate
RutecarpineFructosePhenglutarimideo-Nitrophenol
CarbetapentaneAsphaltOxythiamineEquilin
γ-ErgostenolMequitazineOxymetazolineFirefly Luciferin
©2016 DrugLead US FDA&EMEA